Navigation Links
CombiMatrix Corporation Selects Cartagenia BENCHlab CNV Platform to Bolster Expanded Lab Operations
Date:11/1/2012

BOSTON, Nov. 1, 2012 /PRNewswire/ -- Cartagenia, the world leader in providing genetic labs and clinicians software-based workflow support for variant assessment, lab reporting, and integration of diagnostic knowledge-bases, announced today that it has signed a license agreement for the Cartagenia BENCHlab CNV platform with CombiMatrix Corporation (Nasdaq: CBMX), a molecular diagnostics company.

Irvine, CA-based CombiMatrix is a CLIA-certified and CAP-accredited, publicly-owned commercial clinical laboratory offering DNA-based genomic testing services in the areas of prenatal and pediatric developmental disorders and oncology. CombiMatrix has established itself as an industry leader in microarray-based clinical testing via a core team of microarray-pioneering physicians, scientists and technicians and has a strong commitment to both client and patient-focused service.

BENCH will be used for the analysis, interpretation and reporting of microarray results in routine postnatal and prenatal settings. The flexible nature of the BENCH platform will allow it to be tailored to CombiMatrix's variant assessment and reporting workflow, significantly accelerating the interpretation and reporting process without disrupting the established operating procedures. Additionally, BENCH's architecture will allow integration and communication with existing IT systems at CombiMatrix.

Richard D. Hockett, Jr., M.D.,Chief Medical Officer at CombiMatrix remarked, "With our lab operations and test volumes growing, it made perfect sense to select the Cartagenia BENCH platform at this time. We already perform hundreds of microarray analyses per month and having recently expanded testing for the prenatal marketplace, that number will grow even more. The automation provided by BENCHlab CNV gives us the ability to grow our array throughput while providing significant savings in both analysis and interpretation time and staffing. Another deciding factor was that Cartagenia clearly positions its solutions for clinical use in contrast to other software packages."

"We are pleased and excited to be working with CombiMatrix," said Drew Arnold, Cartagenia's VP of Sales, North America. "Its selection of the BENCH platform is a strong validation of our approach and indicative of the efficiencies that BENCH can bring to diagnostic laboratories."

Cartagenia successfully went through the process of implementing an ISO-certified quality management system and has registered the BENCH platform for variant interpretation and reporting as a Class 1 Medical Device with the FDA.

"We want to provide a 'clinical grade' tool set to our customer and help labs building a reliable infrastructure for clinical use of high-throughput genomic technologies," Arnold added.

About Cartagenia

Cartagenia supplies diagnostic software, database systems, and related services to genetic labs and clinicians, enabling them to perform clinically relevant genetic analyses quickly and efficiently, and offer patients and careers high-quality genetic interpretation and counseling.

The Cartagenia BENCH platform is built in collaboration with genetics labs and clinical experts involved in routine medical practice. Because of this, BENCHlab CNV addresses the specific needs of genetic diagnostic labs and clinicians.

Cartagenia BENCHlab CNV is built using a certified ISO13485 Quality Management System and is marketed as an FDA regulated Class I Medical Device in the United States and as a Class I Medical Device in Europe in conformity with the essential requirements and provisions of the Council Directive 93/42/EEC concerning medical devices, and with the relevant harmonized standards EN ISO62304.

www.cartagenia.com

About CombiMatrix Corporation

CombiMatrix Corporation, through its wholly owned subsidiary, CombiMatrix Molecular Diagnostics, Inc. (CMDX), is a molecular diagnostics laboratory that offers DNA-based testing services to the prenatal, pediatric and oncology markets. The Company performs genetic testing utilizing Microarray, FISH, PCR and G-Band Chromosome Analysis. CMDX offers prenatal and pediatric testing services for the detection of abnormalities of genes at the DNA level beyond what can be identified through traditional technologies. CMDX was also the first commercial clinical laboratory in the United States to make comprehensive DNA-based genomic analysis of solid tumors, including breast, colon, lung, prostate and brain tumors, available to oncology patients and medical professionals. Additional information about CMDX is available at www.cmdiagnostics.com or by calling 1-800-710-0624.

Contact:
CARTAGENIA
Herman Verrelst
CEO Cartagenia
Technologielaan 3
3001 Leuven
T +32 16 40 40 66
E herman.verrelst@cartagenia.com
www.cartagenia.com

ALLEN & CARON
Len Hall
VP Media Relations
T 1 949 474 4300
E len@allencaron.com
www.allencaron.com


'/>"/>
SOURCE Cartagenia
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. United Therapeutics Corporation Reports Third Quarter 2012 Financial Results
2. Fish & Richardson Prevails in Patent Infringement Trial for Volcano Corporation
3. DURECT Corporation Invites You to Join its Third Quarter 2012 Earnings Conference Call
4. Luminex Corporation Reports Third Quarter 2012 Results
5. Unilife Corporation Reschedules Release Of Quarterly Results And Earnings Call Due To Severe Weather In Northeastern U.S.
6. Volcano Corporation Schedules Third Quarter Conference Call, Webcast
7. Unilife Corporation To Announce Financial Results For Fiscal 2013 First Quarter On Tuesday, October 30, 2012
8. Harvest Technologies Corporation reicht Patentverletzungsklage gegen ThermoGenesis Corporation ein
9. Harvest Technologies Corporation Files Patent Infringement Complaint against ThermoGenesis Corporation
10. Sosei Group Corporation: QVA149 Filed as a Once-Daily Maintenance Treatment for COPD in Europe
11. CVS Caremark Corporation Announces New Share Repurchase Authorization for up to $6 Billion of Common Stock
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... A research report by Mordor Intelligence ... reach USD 7.2 billion by the end of 2021 and ... procedure in which a sample is preserved prior to its ... since the methods are often allowing repeated testing. The report ... shared procedures in the lab. In many life science labs, ...
(Date:3/23/2017)... March 23, 2017 Ascendis Pharma A/S (Nasdaq: ... technology to address significant unmet medical needs in rare ... conference call and webcast on Monday, April 3 during ... in Orlando, Florida , to discuss ... (TransCon Growth Hormone, TransCon PTH and TransCon CNP). ...
(Date:3/23/2017)... , March 23, 2017  Cornerstone ... announced a major milestone today.  Following successful ... the U.S. Food and Drug Administration (FDA), ... clinical and regulatory path forward to conduct ... in patients with acute myeloid leukemia (AML) ...
Breaking Medicine Technology:
(Date:3/23/2017)... ... March 23, 2017 , ... Demonstrating their commitment to ... public health departments have been awarded national accreditation through the Public Health ... the expanding network of communities across the nation whose health departments meet rigorous ...
(Date:3/23/2017)... ... 2017 , ... 82% of adults are unaware of the dangers that infectious bacteria play in ... minimum two times a day that dentists recommend. The ramifications of improper oral upkeep go ... and adults missing 164 million hours of work each year due to dental issues. That ...
(Date:3/23/2017)... ... March 23, 2017 , ... ... Angeles based healthcare technology company California Healthcom Group (CHG). , The HUG ... healthcare arena. With headquarters in California, CHG is a growing, internationally recognized healthcare ...
(Date:3/23/2017)... City (PRWEB) , ... March 23, 2017 , ... After ... fall, FaceCradle , the most-funded travel pillow in crowdfunding history, has ... delivery of its wildly popular travel innovation to Americans. , “We’re excited to be ...
(Date:3/23/2017)... ... March 23, 2017 , ... According to the ... poor sleep is likely not the only cause of the sunken-eye look, which can ... you look older or in poor health are likely due to genetics, dehydration, allergies, ...
Breaking Medicine News(10 mins):